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Summary. To demonstrate he efficacy of a premedication 
with H a- -}- H2-receptor antagonists against histamine-re- 
lease responses in anaesthesia and surgery 3 randomized 
controlled trials were conducted in patients, volunteers and 
experimental animals (dogs). Cutaneous anaphylactoid reac- 
tions following infusion of polygeline (Haemaccel ®) in orth- 
opedic patients were successfully abolished by premedica- 
tion with 0.1 mg/kg dimethpyrindene (F nistil) and 5 mg/kg 
cimetidine (Tagamet). Chlorpheniramine (Piriton) was also 
useful, but dimethpyrindene was more effective in the doses 
recommended and used. Side-effects of the premedication 
were not observed when the 2 drugs were slowly admin- 
istered (2 min each). 
Systemic anaphylactoid reactions following infusion of 
polygeline were completely prevented in volunteers by the 
same premedication (0.1 mg/kg dimethpyrindene and 
10 mg/kg cimetidine). Life-threatening reactions could not 
be tested in human subjects, but were elicited in experimen- 
tal animals (dogs). In this species which resembles man in 
its sensitivity against histamine, in plasma histamine levels 
and in response to polygeline life-threatening reactions were 
prevented or in especially severe cases diminished to such 
an extent by the premedication with H 1- + H2-blockers that 
this premedication was finally judged to be very effective 
against histamine-release responses of any grade of severity. 
To confirm this clinically very important hypothesis 
more clinical trims in patients at risk for anaphylactoid 
reactions to drugs are urgently needed. 
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Prophylaxe von anaphylaktoiden Reaktionen 
durch ein Plasmasubstitut auf Polypeptidbasis 
mit Hilfe von H 1- plus H/-Rezeptorantagonisten: 
Synopse von drei randomisierten kontrollierten Studien 
Zusammenfassung. Um die Wirksamkeit einer Pr/imedika- 
tion mit H1- + H2-Rezeptorantagonisten g gen Histamin- 
freisetzungsreaktionen w/ihrend Narkose und Operation 
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nachzuweisen, wurden drei randomisierte kontrollierte 
Studien bei Patienten, Probanden und Versuchstieren 
(Hunden) durchgef/ihrt. Cutane anaphylaktoide Reak- 
tionen nach Infusion yon Polygeline (Haemaccel) wurden 
bei orthop/idischen Patienten durch Prfimedikation mit 
0.1 mg/kg Dimethpyrinden (Fenistil) und 5 mg/kg Cimeti- 
din (Tagamet) nahezu vollst~indig verhindert. Der HI- 
Blocker Chlorpheniramin (Piriton) war ebenfalls wirksam, 
aber es war dem Dimethpyrinden in der empfohlenen Dosis 
an Wirksamkeit unterlegen. Nebenwirkungen der Prfime- 
diaktion wurden bei langsamer Applikation (2 rain) nicht 
beobachtet. 
Systemische anaphylaktoide Reaktionen ach Infusion 
yon Polygeline wurden bei Versuchspersonen durch dieselbe 
Pr/imedikation (0.1 mg/kg Dimethpyrinden und 10 mg/kg 
Cimetidin) vollstfindig verhindert. Lebensbedrohliche 
Reaktionen konnten am Menschen nicht gepriift werden, 
wohl aber beim Hund. Dieselbe Pr/imediaktion wie in den 
beiden vorangehenden Studien (i mg/kg Dimethpyrinden 
und 5 mg/kg Cimetidin) war auBerordenflich erfolgreich 
und verhinderte injedem Falle eine lebensbedrohliche Situ- 
ation. Im Mittel wurden die klinischen Symptome der 
Histaminfreisetzungsreaktion s gar vollst/indig unter- 
drfickt. 
Es wird geschlossen, dab eine Pr/imedikation mit H1- 
plus H/-Rezeptorantagonisten wirksam genug ist, um auch 
beim Patienten Histaminfreisetzungsreaktionen atler 
Schweregrade zuverhindern oder soweit zu verringern, dab 
sic ffir den Patienten keine Gef/ihrdung mehr darstellen. 
Zur Erh/irtung dieser SchluBfolgerung sind weitere klinische 
Studien an Risikopatienten erforderlich. 
Schl/isselwiirter: Pr/imedikation - Dimethpyrinden - Cime- 
tidin - Polygeline - anaphylaktoide R aktion 
Rationale of Testing a Premediaction 
with H1- plus H2-Receptor Antagonists 
To prove the effectiveness of a H 1- and H2-receptor antago- 
nist premedication i reducing or eliminating histamine- 
induced adverse reactions, a controlled clinical trial [3, 4, 
9, 13, 14, 20] must fulfil some very important conditions 
(Table 1). These include the patient's afety since severe 
side-effects are likely to occur [2, 14, 15] and the elucidation 
of the problem as quickly as possible with a minimum of 
Table 1. Requirements for a histamine releaser to study the efficacy 
of H1- and H2-receptor antagonists in clinical trials 
Clinically important and widely used 
No alternative drug available 
Utmost safety provided 
Reasonably pure and chemically defined 
No other drug, solvent or treatment interfering 
Release of histamine predominant, no other mediator interfering 
Incidence reasonably high in clinical situations 
Mechanisms of release sufficiently investigated and rather uniform 
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subjects to be exposed to risk in an extremely complex situa- 
tion which is typical for most clinical conditions. 
Considering these criteria the best known groups of his- 
tamine releasers elected for trial purposes all possess ad- 
vantages and disadvantages (Table 2). Of the muscle relax- 
ants, anaesthetics and colloidal plasma substitutes polyge- 
line (Haemaccel, Behringwerke Marburg, FRG) comes in 
for closer consideration as it is, compared to 48/80, a rela- 
tively weak histamine releaser, can be administered before 
anaesthesia and independent of other drugs [12]. Dextran, 
hydroxyethyl starch and human albumin should be ex- 
cluded. Dextran elicits no unequivocal histamine release in 
man under clinical conditions, but induces a rather complex 
immunological event [2 b]. For hydroxyethyl starch and hu- 
man albumin the pathomechanisms are not known [17]. 
Polygeline was most intensely studied [6, 11]. Histamine 
release was shown to be the predominant cause of it's ad- 
verse reactions, and the mechanism of this seems not to 
involve immunological processes and appears to be very 
uniform [1, 10, 17]. As Fig. 1 shows contained "classical" 
polygeline a defined, but according to our present knowl- 
edge a too great excess of cross-linking material which is 
converted into hexamethylene diamine. This compound re- 
leases histamine [10, 17]. When this was established in ani- 
mals and in man, the product has been improved by reduc- 
ing the amount of cross-linking material so that in a con- 
trolled trial of the currently marketed "purified" polygeline 
in 450 patients, severe (i.e. systemic) anaphylactoid reac- 
tions cotfld no longer be observed [16]. By this way the 
mechanism of histamine release by polygeline in man was 
further confirmed. 
Using both "classical" and "purified" polygeline in hu- 
man subjects and in animals we were able to test the efficacy 
of H1- and H2-receptor antagonists in anaphylactoid reac- 
tions (histamine-release responses) to polygeline in all three 
grades of severity (Table 3). Only controlled clinical trials 
(randomized, prolective, cohort and single or doubleblind 
depending on the data used) were conceived and conducted 
[20]. For ethical reasons this was only possible because 
the trials with "classical" polygetine were carried out first 
at a time when "purif ied" polygeline was not yet avail- 
able. With the latter formulation which has been developed 
in the course of our studies with this plasma substitute 
in cooperation with the company [10] only a clinical trial 
on cutaneous anaphylactoid reactions was carried out. For 
purposes of illustration, however, the time sequence of the 
three trials is converted: We start with the last one dealing 
with cutaneous reactions, procede to the second dealing 
with systemic responses and describe finally the animal 
study which was conducted several years before, but in- 
cludes really very severe reactions which have been found 
in patients only on rare occasions (see Lorenz et al. [12] 
Table 2. Advantages and disadvantages of histamine releasers to be used in clinical trials on the efficacy of H 1- and H2-receptor 
antagonists 
Compounds Advantages Disadvantages 
48/80 
Dextran 
Muscle relaxants 
Anaesthetics 
Contrast media 
Aspirin 
Polygeline 
(Haemaccel) 
Classical liberator, mechanism investigated 
Classical liberator, mechanism investigated 
in animals and cells 
Clinically important and widely used 
Clinically important and widely used 
Clinically important, high incidence 
Clinically important and widely used 
Clinically important and widely used, not 
interfering with other drugs, histamine 
release predominant 
No clinical indication 
No effective releaser in clinical conditions, 
mechanisms not uniform 
Applied in combination with other drugs 
Mechanism not uniform, soh, ents interfering 
Histamine release notpredominant, mechanisms not clear 
Histamine release not predominant, mechanisms not clear 
Classical polygeline no longer applicable, 
purified polygeline o longer effective 
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Table 3. Classification of histamine-release responses by severity as a special form of anaphylactoid reaction to drugs (for details 
of definition and classification see Lorenz et al. [12] 
Severity Clinical symptoms Operational criteria Plasma 
grade and histamine 
groups of symptoms [ng/ml] 
I. 
Cutaneous 
anaphylactoid 
II. 
Systemic 
anaphylactoid 
III. 
Life-threatening 
anaphylactoid 
Erythema, urticaria nd/or dermal 
pruritus only 
Generalized skin reactions plus discomfort 
tachycardia, rrhythmias, medium hypotension 
respiratory distress 
Severe hypotension (pulse and RR not 
measurable) 
ventricular fibrillations, cardiac arrest 
bronchospasm, respiratory arrest 
Not considered as threating 
No intensified observation, o treatment 
Considered as threatening bypatient 
and doctor 
Intensified observation and/or treatment 
Considered as life-threatening by doctor 
Emergency treatment 
-< 1 ng/ml 
> 1 ng/ml 
> 12 ng/ml 
Table 4. Synopsis of randomized controlled trials on prevention ofanaphylactoid reactions to polygeline by premedication with histamine 
H1- and Hi-receptor antagonists 
Trial Severity of Histamine reIeaser H 1-+ H/-receptor Frame of the trial 
No. reaction (Polygeline) antogonists 
[mg/kg i.v.] 
1 Cutaneous Purified H 1 : Fenistil 0.1 
anaphylactoid 7 ml/kg, 10-15 min Piriton 0.3 
H2: Tagament 5.0 
2 Systemic Classical H1 : Fenistil 0.1 
anaphylactoid 7 ml/kg, 3 min Hz: Tagamet 10.0 
3 Life-threatening Classical and purified H 1 : Fenistil 1.0 
anaphylactoid 20 ml/kg, 3 min H z : Tagamet 5.0 
Randomized controlled single and double-blind 
450 patients, Heidelberg 1979/80 
Randomized controlled single and double-blind 
50 volunteers, Munich 1977 
Randomized controlled 
40 dogs, Marburg 1977 
in this issue). We will be able to show that even these very 
severe reactions can be successfully prevented by a premedi- 
cation with Ha- and H2-receptor antagonists. 
Materials and Methods 
The synopsis of the three randomized controlled trials is compiled 
in Table 4, the details will be given in the following sections. The 
structural formulae of the H 1- and H2-receptor antagonists mostly 
used in this communication are shown i  Fig. 2. 
Trial 1: Cutaneous Anaphylaetoid Reactions [16] 
A prolective, cohort, randomized, partly single-blind (clinical 
symptoms), partly double-blind (plasma histamine) placebo-con- 
trolled clinical trim was performed in 450 orthopaedic patients 
in Heidelberg in 1979/80. The aims of the study were to test whether 
cutaneous and systemic anaphylactoid reactions to polygeline 
could be prevented by premedication with H 1- and Hz-receptor 
antagonists. However, only one of the two questions could be ans- 
wered at the end of the study since due to "purification" of polyge- 
line only cutaneous anaphylactoid reactions occurred in the control 
group and plasma histamine l vels never xceeded 1 ng/ml plasma 
indicating that also in the H 1- and Hz-receptor antagonist pre- 
treated groups no pathological plasma histamine levels [12] were 
produced by polygeline. 
Premedication a d polygeline were administered before general 
anaesthesia and operation. No further premedication was applied 
at the day of operation 2 h before the specific premedication a d 
polygeline were administered. 
The 450 patients comprised both sexes, divided into 5 classes 
of age (20- >_ 60 years, 30 patients in each class) according to Sch6n- 
ing and Koch [13]. The patients were without exception due to 
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Fig. 2. Structural formulae of dimethpyrindene and cimetidine, the 
two mostly used H1- and H2-blocker in this communication 
undergo elective surgery during the morning or early afternoon. 
Casualty and outpatients a well as emergency cases were excluded. 
The study had 2 test groups and 1 control group. Test group 1 
received the Hi-blocker dimethpyrindene (Fenistil, Zyma-Blaes 
GmbH Munich, FRG) and the H2-blocker cimetidine (Tagamet, 
SK&F Dauelsberg, Munich-G6ttingen, FRG). Test group 2 re- 
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Fig. 3. Photograph of the original EDA protocoI used in trial 1 
on cutaneous anaphylactoid reactions. For development of this 
questionnaire s e Lorenz et al. [12] 
ceived the Hi-blocker chlorpheniramine (Piriton, Allen & Han- 
burys, London, UK) and the H2-blocker cimetidine. The control 
group received the same volume of saline as used for the two 
drug applications in the test groups before the infusion of polyge- 
line. Dimethpyfindene (0.1 mg/kg) was given i.v. in a volume of 
20 ml within exactly 2 rain, chlorpheniramine (0.3 mg/kg) and ci- 
metidine (5 mg/kg) were administered i.v. in the same volume and 
in exactly the same time. Cimetidine was always applied beJore 
the Hcblocker as described in a previous communication [9]. 
Fifteen rain after starting the premedication polygeline (Hae- 
maccel) was infused in a dose of 500 ml/patient over 10 min. 10 
batches produced in January 1979 were randomly applied. Anaes- 
thesia started 30 rain after beginning the infusion. The clinical 
symptoms or physical alterations caused by the reactions were re- 
corded or measured using a fixed EDA protocol (Fig. 3). Further- 
more pulse rate, blood pressure and plasma histamine concentra- 
tions (in the saline and in the cimetidine-dimethpyrindene group) 
were measured. For plasma histamine 3 blood samples were taken 
at fixed intervals - before premedication as well as 5 and 10 rain 
after the beginning of the infusion. Plasma was prepared already 
in the operation theatre in a Christ Minifuge according to Lorenz 
et al. (5) and histamine was measured fluorometrically asdescribed 
in [5]. Quality control samples were included in every run and 
control charts were used as mentioned in [12]. 
Trial 2: Systemic Anaphylactoid Reactions [9] 
A prolective, cohort, randomized, single-blind (clinical symptoms) 
and double-blind (plasma histamine) placebo-controlled trial was 
performed in 50 male, healthy volunteers (Table 5) in Munich (July 
1977). The aim of the study was to test whether the combined 
i.v. administration of dimethpyrindene and cimetidine could pre- 
vent systemic anaphylactoid reactions following i.v. infusion of 
classical polygeline (Table 4). 
Tab le  5. Atributes of the 50 volunteers in trial: Systemic anaphylac- 
toid reactions 
Attributes 
of the volunteers 
Groups for pretreatment 
Saline H t + H 2- 
blocker 
(n = 25) (n = 25) 
Age 25 (22-28) 24 (22-26) 
(years, ff (lst-3rd quartile)) 
Weight 74 (70-82) 72 (67-75) 
(kg, Y (Ist-3rd quartile)) 
Profession 12/11/2 13/8/4 
(S-NM, S-M, others) 
Allergy - now 8/17 15/10 
(yes/no) 
Allergy - more than 7/18 9/16 
9 months ago (yes/no) 
Professions: S-NM=student, non-medical, S-M=medical stu- 
dents, others = other professions ( ee [7]) 
Dimethpyrindene (0.1 mg/kg) and cimetidine (10 mg/kg) or sa- 
line as placebo solution were randomly applied to the volunteers 
(first cimetidine in 20 s, 10 s later dimethpyfindene i  2 rain). 
10 rain later the plasma substitute was applied without any 
other medication following blood donation of 440 ml. The dose 
was 500 ml/volunteer corresponding to about 7 ml/kg on the aver- 
age, the infusion time was 3 rain. Two batches of Haemaccel were 
randomly applied including the product numbers Op 3939 and 
Op 3946. Random assignment of the volunteers to the premedica- 
tion and polygeline groups was performed always by using random 
digits. The clinical symptoms of the reactions were recorded by 
a specified questionnaire [7]which has been published as an origi- 
nal protocol in Lorenz et al. [12]. Heart rate (lead II in ECG), 
blood pressure (sphygmomanometric) andplasma histamine (fluor- 
ometric) were determined as described in detail in three previous 
communications [7, 9, 12]. Blood was taken for plasma histamine 
assays twice before injecting the antagonists, 3 rain after their appli- 
cation and again 1,5, 10 and 20 rain after the end of the polygeline 
infusion. Top plasma histamine levels were chosen to define the 
extent of the histamine release [12]. 
The observation period was confined to 60 rain. In cases of 
systemic anaphylactoid reactions to polygeline stop of infusion was 
mandatory. Treatment included oxygen, sympathicomimetics, pre- 
dnisolone, Hi-receptor antagonists and orciprenaline. For further 
conditions and ethical considerations see in detail Lorenz et al. 
[121. 
Trial 3: Life-threatening Anaphylactoid Reactions [8] 
A prolective, cohort, randomized trial was conducted in 40 adult 
mongrel dogs of both sexes weighing 22-32 kg. The animals were 
kept separately in cages for a few days, were vaccinated against 
distemper, leptospirosis and canine hepatitis by Candur SHL 
(Behringwerke Marburg) and fed by standard food (Nagut-Vibro- 
mix, Dr. Mfiller, Lage, FRG) and tap water ad libitum. 
The aim of the study was to test whether the combined applica- 
tion of dimethpyrindene and cimefidine could prevent life-threaten- 
ing anaphylactoid reactions following rapid infusion of classical 
polygeline. Since "purified" polygeline was expected not to cause 
histamine release neither anaphylactoid reactions nor any hista- 
mine release or any other side-effects of the premedication and 
the potygeline infusion should have been observed (additional con- 
trol groups in the trial !) (Table 4). 
The dogs were anaesthetized with 15-25 mg/kg pentobarbitone 
i.v. and breathed room air spontaneously after intubation. Three 
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Fig. 4. Plasma histamine levels in orthopedic patients 
before premedication. 300 patients were investigated, 
(1 plasma was lost), n=299.2=0.35 ng/ml, range=0- 
0.9 ng/ml 
polyethylene catheters were inserted, one into the v. cava inferior 
(infrahepatic) via the right femoral vein for infusing the plasma 
substitute and collecting the blood for whole blood histamine deter- 
ruination. Whole blood histamine assay is easier than plasma hista- 
mine assay, and in dogs whole blood histamine determinations 
can replace plasma histamine determinations since dogs have a
very low whole blood histamine level due to a very small number 
of basophils [8, I t]. The other two catheters were inserted both 
into the aorta, one for measuring the arterial blood pressure by 
a Statham pressure transducer and Hellige compensograph, the 
other for a rapid bleeding (for details see Vars et al. [19] and 
Messmer et al. [12@ After these manipulations the animals were 
a/lowed to recover for 20 rain [18]. 
Dimethpyrindene (1 mg/kg) and cimetidine (5 mg/kg) or saline 
as a placebo solution were administered i.v. (first cimetidine in 
20 s, 10 s later dimethpyrindene i  2 rain!). After 10 rain 20 ml/kg 
blood were removed and 1 min later replaced by the same volume 
of polygeline within 3 min. 2 batches of classical polygeline 
(Op 3939, Op 3946) and 2 batches of purified polygeline (V-244 
and V-265) were administered. Again the animals were assigned 
to any of the pretreatment or polygeline groups by random digits. 
Clinical symptoms were assessed by 2 observers, the blood pres- 
sure (systolic, diastolic) was continuously monitored and blood 
histamine levels were determined by the combined fluorometric 
assay of Lorenz and Doenicke [8]. 5 ml blood were taken twice 
before premedication, 3 min after premedication a d 1, 5, 10, 20 
and 30 min after potygetine infusion. Histamine levels were always 
expressed as top levels according to Lorenz et al. [12, 18]. 
Results 
Trial 1 : Cutaneous Anaphylactoid Reactions [16] 
It was not intended in this trial to study only cutaneous 
anaphylactoid reactions. In contrast, however, to the now 
outdated formulations of Haemaccel [9, 12, 13] "pur i f ied"  
polygeline [10] did not elicite any systemic anaphylactoid 
reaction in the patients, neither in the test groups nor in 
the control groups receiving only saline as a "premedica-  
t ion"  (Table 6). This considerable improvement of  the drug 
could be demonstrated by calculating the confidence inter- 
vals for the incidences of systemic reactions in the 3 samples 
hitherto investigated (0(0-2.4%)/150 patients (this paper), 
30(3.4-7.1%)/600 patients [9, 12] and 9(2.7- 11.2%)/150 
patients [13]. 
There were, however, still cutaneous anaphylactoid re- 
actions. They did not have a detectable clinical significance 
since they consisted only of  wheals of  2-3 mm diameter 
Table 6. Cutaneous anaphylactoid reactions in patients receiving 
3 kinds of premedication and subsequent infusion of "purified 
polygeline" 
Premedication Patients with No Total 
Anaphylactoid reaction 
reaction 
systemic cutaneous 
Saline 0 27 t 23 150 
Fenistil plus 0 4 146 150 
Tagamet (H 1 + H2) 
Piriton plus 0 9 141 150 
Tagmet (H 1 + H2) 
Total 0 40 410 450 
Total (H 1 + H2) versus aline: Z 2 = 24,11 (p < 0.005) 
Table 7. Quantification of cutaneous anaphylactoid reactions in 
patients receiving 3 kinds of premedication a d subsequent infu- 
sion of "purified polygeline" 
Premedication Number of wheals/Patient 
reacting with a cutaneous 
anaphylactoid reaction 
< 5 > 5 Total 
Saline 12 t 5 27 
Fenistil plus Tagamet 4 0 4 
Piriton plus Tagmet 7 2 9 
Total 23 17 40 
(Table 7). The incidence of this banale histamine-release 
response [12] to polygeline was less than in previous tudies 
[9, 12], but still 18%. However, by premedication with H 1- 
plus Hz-receptor antagonists it was drastically reduced, not 
only in the overall number of  reactions (Table 6), but also 
in the "sever i ty" of  the residual ones (Table 7). Fenistil 
in the dose used was uperior to Piriton in the dose used 
both of  them being recommended by the corresponding 
companies. 
Table 8. Medians of plasma histamine levels before premedication 
and after infusion of "purified polygeline" (plasma samples of 
one patient were lost) 
Response to N Plasma histamine l vel 
polygeline (ng/ml) 
Before After start 
premedi- of infusion 
cation 
5 min 10 min 
No reaction 259 0.35 0.3 0.4 
Cutaneous reaction 40 0.3 0.35 0.4 
Table 9. Systemic anaphylactoid reactions in volunteers r ceiving 
2 kinds of premedication a d subsequent rapid infusion of "classi- 
cal" polygeline 
H1 +H2 versus saline: Z2=4.76 (0<0.05) 
Premedication Reactions 
systemic anaphylactoid 
yes no Total 
Saline 6 19 25 
Fenistil plus Tagamet 0 25 25 
Total 6 44 50 
In agreement with previous extended studies [6, 8, 11, 
12] the basal plasma histamine levels in all patients were 
within the normal range (Fig. 4). In the literature never 
a sample size of  about 300 subjects was investigated. Thus 
this was the first study which showed in a statistically con- 
vincing manner that the basal plasma histamine level was 
not normally distributed, that the range was <0.1 ng-  
0.9 ng/ml and the median was about 0.3 ng/ml. Again in 
agreement with a previous study [12] the plasma histamine 
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concentration did not attain a pathological level of > 1 ng/ 
mt. On the average it was not different from the pre-infusion 
level (Table 8). In addition, no difference in plasma hista- 
mine levels could be detected between subjects with "no 
reaction" and those with "cutaneous reaction" (Table 8). 
Trial 2: Systemic Anaphytactoid Reaction [9] 
In volunteers receiving saline as a "premedication" fol- 
lowed by a rapid infusion of classical polygeline 6 systemic 
and 9 cutaneous anaphylactoid reactions were observed. 
None of them occurred in subjects of the test group pre- 
treated by dimethpyrindene and cimetidine (Table 9). Two 
of the 6 systemic histamine-release re ponses had a consid- 
erable severity [7]: mild bronchospasm, generalized urti- 
caria with great discomfort (blepharoedema, cough, sneez- 
ing, stuffy nose) and subjective fear for life occurred along 
with tachycardia nd mild hypertension. 
It was remarkable that the maximum plasma histamine 
levels in these two subjects were only about 2 ng/ml 
(Table 10). However, also in the 4 other volunteers develop- 
ing systemic reactions following polygeline pathological 
plasma histamine concentrations (> 1 ng/ml) were detected 
supporting the definition and classification of histamine- 
release responses described by Lorenz et at. [12]. In the 
test group receiving H1- and H2-receptor antagonists 7 vo- 
lunteers reacted by histamine release following polygeline 
infusion. The extent of  release was even greater than in 
the control group including 2 subjects with plasma hista- 
mine values of  5 ng/ml. Since in a series of previous tudies 
[6, t 1, 12] increases of plasma histamine levels in this order 
of magnitude always caused considerable systemic anaphy- 
lactoid reactions to polygeline the complete prevention of 
any clinical signs and circulatory reactions n these volun- 
teers seemed very remarkable. 
Tachycardia s the most sensitive parameter of  systemic 
histamine-release r sponse [12] was present in 5 of the 6 
volunteers with placebo premedication and histamine re- 
lease by polygeline (Table 10). However, none of the sub- 
jects receiving Hj  + H2-receptor antagonists showed any in- 
crease in heart rate (> 5 beats/min). 
Table 10. Tachycardia nd hypertension following rapid infusion of "classical" polygeline in volunteers with systemic anaphylactoid 
reactions, but pretreated with placebo (saline) or dimethpyrindene and cimetidine 
No Saline No. 
name name 
H 1 + H2-receptor antagonists 
Plasma histamine Hyper- Tachy- Plasma histamine Hyper- Tachy- 
level (ng/ml) tension cardia level (ng/ml) tension cardia 
(mm Hg) (beats/rain) (mm Hg) (beats/min) 
before after before after 
3 M.S. 0.1 1.25 10/5 12 2 W.J. 0.3 1.8 0 0 
16 D.P. 0.2 t.8 = 20/10 26 17 D.H. 0.3 5.1 0 0 
41 M.W. 0.3 2.2 a 0 23 21 B.K. 0.25 1.5 0 0 
44 V.M. 0.6 1.1 0 22 22 R.C. 0.2 5.0 0 0 
47 S.R. 0.25 1.2 0 0 25 K.J. 0.1 3.1 0 0 
48 P.K. 0.1 1,t 0 16 28 D.M. 0.5 1.l 5/5 0 
. . . . . . .  34 T.A. 0.75 1.3 0 0 
Total 0.25 1.25 2/6 5/6 Total 0.3 1.8 1/7 0/7 
(0.1-0.6) (1.1-2.8) (0.1-0.75 (1.1-5,1) 
Numbers according to the course of the controlled clinical trial. 2 ~ (range) or incidences Hypertension as systolic/diastolic pressure 
"Subjects uffering from a considerable, but not life-threatening reaction 
Significance in Fisher's exact test p < 0.05 for tachycardia 
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Tab le  11. Prevention of severe, life-threatening a aphylactoid reac- 
tions in dogs following rapid infusion of "classical" polygeline 
by premedication with H 1- and Ha-receptor antagonists 
Rank Increase in histamine Hypotension 
[ng/ml] [mm Hg] 
Saline H1-1- [:[2 Saline H 1 + H2 
1 5 .3  0 0 0 
2 10.1 1.2 30 0 
3 2I .3 2.9 35 0 
4 37.5 8.4 60 0 
5 42.5 19.6 110 0 
6 55.2 22.7 120 0 
7 69.4 48.7 140 0 
8 72.0 52.2 150 30 
9 107.5 62.2 170 30 
10 - 91 .3  - 40 
11 - 113 .7  - 50 
Median 42.5 22.7" 110 0 b 
(Range) (5.3-107.5) ((~113.7) (~-170) (0--50) 
Investigators measuring blood histamine levets were not aware of 
the blood pressure responses. Investigators injecting the premedica- 
tion did not know the composition of the fluid used in the syringes. 
Increase in blood histamine levels and hypotension (decrease in 
systolic blood pressure) are given for the time of maximum re- 
sponse (about I-5 min after the end of the infusion). Statistical 
analysis using the Mann-Whitney test: Saline versus H I + H 2 
Increase in histamine notsignificant 
b Hypotension p < 0.01 
Trial 3: Life-threatening AnaphyIactoid Reactions [8] 
All dogs except one reacted to "classical" potygeline by 
a systemic histamine-release response (Table 11). More than 
half of them were life-threatening, with hypotensive reac- 
tions of more than 100 mm Hg. The time course of such 
Haemaccel shocks both with regard to blood pressure and 
whole blood histamine changes had been illustrated by 
Messmer et at. [12 a], demonstration f curves was therefore 
omitted in this communication. 
Instead of plasma histamine levels whole blood concen- 
trations were measured in dogs (for easons ee Materials 
and Methods). An increase by about 40 ng/ml whole blood 
corresponded to about 10 ng/ml plasma (Fig. 6 in Lorenz 
et at. [22]) which in human subjects caused life-threatening 
anaphylactoid reactions, too [12]. The premedication by 
H1 +Ha-receptor antagonists did not change significantly 
the extent of histamine release licited by "classical" poly- 
geline (Table 11). About half of the blood histamine con- 
centrations were higher than 40 ng/ml in the saline and 
the H i + Ha-group. 
In contrast o that, however, was the hypotensive re- 
sponse to polygeline drastically reduced by premedication 
with H 1 + H2-receptor antagonists (Table 11). On the aver- 
age, the blood pressure decrease was completely prevented. 
In the least successful pretreatment it was diminished to 
50 mm Hg (Table 11) - a hypotension which was well toler- 
ated by the animal and which disappeared after 20 min. 
Infusion of "purif ied" polygeline did not elicite any 
life-threatening anaphylactoid reaction in dogs - either pre- 
treated by saline or by H~ + Ha-receptor antagonists. There 
was only a slight hypotension of 40 mm Hg in one animal 
in the saline group and no hypotension at all in the H I + H 2- 
group.  In each group only one animal showed an increase 
in blood histamine levels, 1.9 ng/mt in the saline group and 
1.1 ng/ml in the H~ +H2-group. Thus there was no indica- 
tion that pretreatment with dimethpyrindene and cimetidine 
either altered the histamine release [2a] nor had an influ- 
ence on the catabolism of the released histamine [18]. 
Discuss ion  
Histamine liberation by drugs used in anaesthesia and sur- 
gery was demonstrated now in patients, volunteers and ex- 
perimental animals in clinical conditions' [6-12]. There is 
a tremendous variety of substances which elicite histamine- 
release responses as adverse reactions. Hitherto we do not 
know how dangerous an average reaction [12] is for the 
intra- and postoperative period of an individual patient. 
There is, however, no doubt that some of the reactions 
are life threatening [12] and some of them also end with 
the immediate death of the patient [2]. 
Three questions arise from these clinical observations: 
(1) Is the incidence of histamine release high in patients 
during routine anaesthesia and surgery? The 3 controlled 
trials in this communication give only a limited answer to 
this very urgent question. (2) Can the clinical effects of 
histamine release be prevented by a premedication with 
H1 +Ha-receptor antagonists? We suggest hat this prob- 
lem has been solved very convincingly with polygeline (Hae- 
maccel) as a prototype substance. (3) Are there any side- 
effects of such a premedication? We suggest hat from the 
data accumulated in the three trials and in a previous tudy 
[9] it became apparent hat with dimethpyrindene as an 
Hi-receptor antagonist and cimetidine as an Ha-receptor 
antagonist in the doses and the speed of administration used 
in man this question also can be answerd in favour of the 
H1 + H2-blockade. In the first trial in 450 patients 300 were 
pretreated by H1- and Ha-receptor antagonists. No cardiac 
arrhythmia, no other side-effects were observed when the 
H 1- and Ha-receptor antagonists were injected slowly each 
in 2 min [9, 10, 16]. Chlorpheniramine (Piriton) and cimeti- 
dine, but not dimethpyrindene (Fenistil) released histamine 
in volunteers when the drugs were administered as a bolus 
injection [9]. Dimethpyrindene can replace chlorphenira- 
mine, but for cimetidine (one of the best investigated drugs 
in our time) hitherto there is no better alternative. Raniti- 
dine also elicites histamine release when applied as a bolus 
injection in human volunteers [I i]. 
The premedication with H1- and Ha-receptors antago- 
nists was effective against cutaneous anaphylactoid reac- 
tions elicited by histamine release. It was, however, neces- 
sary to use the antihistaminic drugs for prophylaxis. Treat- 
ment of the reactions by Hi+Ha-blockade proved to be 
unsuccessful [7]. Systemic anaphylactoid reactions by poly- 
geline in human volunteers also could be prevented com- 
pletely by premedication with Hi- and Ha-receptor antago- 
nists. There is, however, no evidence that patients in general 
and especially patients at risk (advanced age, tumors or 
septical complications, respiratory and cardiac insuffi- 
ciency) can be protected from the effects of released hista- 
mine with the same efficacy as healthy volunteers. The re- 
sults of trial 2 seemed to be very promising, but more clini- 
cal trials are needed to establish the high efficacy of an 
H 1 + Ha-blockade against histamine mediated adverse reac- 
tions. 
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Life-threatening reactions could not be produced in vo- 
lunteers or patients to test the efficacy of a premedication. 
Thus the animal species was chosen which with regard to 
histamine sensitivity, plasma histamine levels and response 
to polypeptidal plasma substitutes was shown to be the 
most similar to human subjects: the dog [8, 10, 11, 12a, 
18, 22]. In this species life-threatening histamine-release re-
sponses were caused by polygeline, but could be prevented 
by the premedication with Hz- and H2-receptor antagonists. 
This result seemed to be very promising for testing this 
premedication also in patients at risk: subjects who already 
suffered from a histamine-release response of any grade 
of severity, patients with an allergic constitution (hay fever, 
asthma, allergic exanthema etc.), patients with diseases in 
whom immunological reactions are considered to be very 
common (tumor patients or those with suppurative pro- 
cesses). 
There are other ways to protect patients from anaphy- 
lactoid reactions in general and more specifically from his- 
tamine-release r sponses. They have been successfully pur- 
sued in the past decade - the discarding of some histamine- 
releasing drugs [23], development of  better drugs [2a] and 
solvents [11], l imitation of  prescribing indications, and 
avoidance of  unduly rapid administration. Polygeline is a 
prototype drug for such a development: instead of produc- 
ing consistently new substances the effects and side-effects 
of  which are not well known for many years of clinical 
experience it is much more preferable to improve "o ld"  
drugs by a systematic research: "Pur i f ied"  polygeline no 
longer elicited systemic anaphylactoid reactions in patients. 
Other approaches such as premedication ~th  low-molecu- 
lar dextran, to prevent dextran induced anaphylactoid reac- 
tions, are very appreciated, too [2b]. 
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